BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

636 related articles for article (PubMed ID: 27692977)

  • 1. Comparison of Inhaled Antibiotics for the Treatment of Chronic Pseudomonas aeruginosa Lung Infection in Patients With Cystic Fibrosis: Systematic Literature Review and Network Meta-analysis.
    Elborn JS; Vataire AL; Fukushima A; Aballea S; Khemiri A; Moore C; Medic G; Hemels ME
    Clin Ther; 2016 Oct; 38(10):2204-2226. PubMed ID: 27692977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosis.
    Littlewood KJ; Higashi K; Jansen JP; Capkun-Niggli G; Balp MM; Doering G; Tiddens HA; Angyalosi G
    J Cyst Fibros; 2012 Sep; 11(5):419-26. PubMed ID: 22717535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients.
    Flume PA; VanDevanter DR; Morgan EE; Dudley MN; Loutit JS; Bell SC; Kerem E; Fischer R; Smyth AR; Aaron SD; Conrad D; Geller DE; Elborn JS
    J Cyst Fibros; 2016 Jul; 15(4):495-502. PubMed ID: 26852040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection.
    Greenwood J; Schwarz C; Sommerwerck U; Nash EF; Tamm M; Cao W; Mastoridis P; Debonnett L; Hamed K
    Ther Adv Respir Dis; 2017 Jul; 11(7):249-260. PubMed ID: 28614995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis.
    McCoy KS; Quittner AL; Oermann CM; Gibson RL; Retsch-Bogart GZ; Montgomery AB
    Am J Respir Crit Care Med; 2008 Nov; 178(9):921-8. PubMed ID: 18658109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients.
    Stuart Elborn J; Geller DE; Conrad D; Aaron SD; Smyth AR; Fischer R; Kerem E; Bell SC; Loutit JS; Dudley MN; Morgan EE; VanDevanter DR; Flume PA
    J Cyst Fibros; 2015 Jul; 14(4):507-14. PubMed ID: 25592656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhaled antibiotics for the treatment of chronic bronchopulmonary Pseudomonas aeruginosa infection in cystic fibrosis: systematic review of randomised controlled trials.
    Máiz L; Girón RM; Olveira C; Quintana E; Lamas A; Pastor D; Cantón R; Mensa J
    Expert Opin Pharmacother; 2013 Jun; 14(9):1135-49. PubMed ID: 23586963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colistimethate sodium powder and tobramycin powder for inhalation for the treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis: systematic review and economic model.
    Tappenden P; Harnan S; Uttley L; Mildred M; Carroll C; Cantrell A
    Health Technol Assess; 2013 Dec; 17(56):v-xvii, 1-181. PubMed ID: 24290164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection.
    Elborn JS; Flume PA; Cohen F; Loutit J; VanDevanter DR
    J Cyst Fibros; 2016 Sep; 15(5):634-40. PubMed ID: 26935334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aerosolized antibiotics in cystic fibrosis: an update.
    Fiel SB
    Expert Rev Respir Med; 2014 Jun; 8(3):305-14. PubMed ID: 24838090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
    Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL
    N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
    Langton Hewer SC; Smyth AR
    Cochrane Database Syst Rev; 2014 Nov; (11):CD004197. PubMed ID: 25383937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tobramycin inhalation powder in cystic fibrosis patients: response by age group.
    Geller DE; Nasr SZ; Piggott S; He E; Angyalosi G; Higgins M
    Respir Care; 2014 Mar; 59(3):388-98. PubMed ID: 23983274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost effectiveness of dry powder antibiotics for the treatment of Pseudomonas aeruginosa in patients with cystic fibrosis.
    Tappenden P; Harnan S; Uttley L; Mildred M; Walshaw M; Taylor C; Brownlee K
    Pharmacoeconomics; 2014 Feb; 32(2):159-72. PubMed ID: 24338264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis.
    Flume PA; Clancy JP; Retsch-Bogart GZ; Tullis DE; Bresnik M; Derchak PA; Lewis SA; Ramsey BW
    J Cyst Fibros; 2016 Nov; 15(6):809-815. PubMed ID: 27233377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An 8 week open-label interventional multicenter study to explore the lung clearance index as endpoint for clinical trials in cystic fibrosis patients ≥8 years of age, chronically infected with Pseudomonas aeruginosa.
    Sutharsan S; Naehrig S; Mellies U; Sieder C; Ziegler J
    BMC Pulm Med; 2020 Jun; 20(1):167. PubMed ID: 32532226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.
    Chuchalin A; Csiszér E; Gyurkovics K; Bartnicka MT; Sands D; Kapranov N; Varoli G; Monici Preti PA; Mazurek H
    Paediatr Drugs; 2007; 9 Suppl 1():21-31. PubMed ID: 17536872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for the efficacy of aztreonam for inhalation solution in the management of Pseudomonas aeruginosa in patients with cystic fibrosis.
    Hansen C; Skov M
    Ther Adv Respir Dis; 2015 Feb; 9(1):16-21. PubMed ID: 25471692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study.
    Tiddens HA; De Boeck K; Clancy JP; Fayon M; H G M A; Bresnik M; Derchak A; Lewis SA; Oermann CM;
    J Cyst Fibros; 2015 Jan; 14(1):111-9. PubMed ID: 25091537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic approaches to chronic cystic fibrosis respiratory infections with available, emerging aerosolized antibiotics.
    Ballmann M; Smyth A; Geller DE
    Respir Med; 2011 Dec; 105 Suppl 2():S2-8. PubMed ID: 22208546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.